Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230.

Scaria PV, Rowe CG, Chen BB, Muratova OV, Fischer ER, Barnafo EK, Anderson CF, Zaidi IU, Lambert LE, Lucas BJ, Nahas DD, Narum DL, Duffy PE.

NPJ Vaccines. 2019 Jul 8;4:24. doi: 10.1038/s41541-019-0121-9. eCollection 2019.

2.

Host cell protein quantification of an optimized purification method by mass spectrometry.

Reiter K, Suzuki M, Olano LR, Narum DL.

J Pharm Biomed Anal. 2019 Sep 10;174:650-654. doi: 10.1016/j.jpba.2019.06.038. Epub 2019 Jun 28.

PMID:
31279895
3.

Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women.

Teo A, Randall LM, Madanitsa M, Mwapasa V, Phiri LK, Khairallah C, Buffet C, Karahalios A, Narum DL, Kuile FOT, Rogerson SJ.

Sci Rep. 2019 May 27;9(1):7878. doi: 10.1038/s41598-019-44340-x.

4.

Functional Antibodies against Placental Malaria Parasites Are Variant Dependent and Differ by Geographic Region.

Doritchamou J, Teo A, Morrison R, Arora G, Kwan J, Manzella-Lapeira J, Medina-Maldonado S, Langhorne J, Hviid L, Narum DL, Dicko A, Fried M, Duffy PE.

Infect Immun. 2019 Jun 20;87(7). pii: e00865-18. doi: 10.1128/IAI.00865-18. Print 2019 Jul.

PMID:
30988054
5.

Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice.

Coelho CH, Gazzinelli-Guimaraes PH, Howard J, Barnafo E, Alani NAH, Muratova O, McCormack A, Kelnhofer E, Urban JF Jr, Narum DL, Anderson C, Langhorne J, Nutman TB, Duffy PE.

Vaccine. 2019 Feb 14;37(8):1038-1045. doi: 10.1016/j.vaccine.2019.01.027. Epub 2019 Jan 23.

6.

Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A.

Burkhardt M, Reiter K, Nguyen V, Suzuki M, Herrera R, Duffy PE, Shimp R Jr, MacDonald NJ, Olano LR, Narum DL.

Vaccine. 2018 Sep 24. pii: S0264-410X(18)31297-0. doi: 10.1016/j.vaccine.2018.09.037. [Epub ahead of print]

PMID:
30262247
7.

Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.

Sagara I, Healy SA, Assadou MH, Gabriel EE, Kone M, Sissoko K, Tembine I, Guindo MA, Doucoure M, Niaré K, Dolo A, Rausch KM, Narum DL, Jones DL, MacDonald NJ, Zhu D, Mohan R, Muratova O, Baber I, Coulibaly MB, Fay MP, Anderson C, Wu Y, Traore SF, Doumbo OK, Duffy PE.

Lancet Infect Dis. 2018 Sep;18(9):969-982. doi: 10.1016/S1473-3099(18)30344-X. Epub 2018 Jul 27.

PMID:
30061051
8.

NK cells inhibit Plasmodium falciparum growth in red blood cells via antibody-dependent cellular cytotoxicity.

Arora G, Hart GT, Manzella-Lapeira J, Doritchamou JY, Narum DL, Thomas LM, Brzostowski J, Rajagopalan S, Doumbo OK, Traore B, Miller LH, Pierce SK, Duffy PE, Crompton PD, Desai SA, Long EO.

Elife. 2018 Jun 26;7. pii: e36806. doi: 10.7554/eLife.36806.

9.

TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25.

Thompson EA, Ols S, Miura K, Rausch K, Narum DL, Spångberg M, Juraska M, Wille-Reece U, Weiner A, Howard RF, Long CA, Duffy PE, Johnston L, O'Neil CP, Loré K.

JCI Insight. 2018 May 17;3(10). pii: 120692. doi: 10.1172/jci.insight.120692. eCollection 2018 May 17.

10.

Antibody levels to recombinant VAR2CSA domains vary with Plasmodium falciparum parasitaemia, gestational age, and gravidity, but do not predict pregnancy outcomes.

Fried M, Kurtis JD, Swihart B, Morrison R, Pond-Tor S, Barry A, Sidibe Y, Keita S, Mahamar A, Andemel N, Attaher O, Dembele AB, Cisse KB, Diarra BS, Kanoute MB, Narum DL, Dicko A, Duffy PE.

Malar J. 2018 Mar 9;17(1):106. doi: 10.1186/s12936-018-2258-9.

11.

Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity.

Scaria PV, Chen B, Rowe CG, Jones DS, Barnafo E, Fischer ER, Anderson C, MacDonald NJ, Lambert L, Rausch KM, Narum DL, Duffy PE.

PLoS One. 2017 Dec 27;12(12):e0190312. doi: 10.1371/journal.pone.0190312. eCollection 2017.

12.

Profiling invasive Plasmodium falciparum merozoites using an integrated omics approach.

Kumar K, Srinivasan P, Nold MJ, Moch JK, Reiter K, Sturdevant D, Otto TD, Squires RB, Herrera R, Nagarajan V, Rayner JC, Porcella SF, Geromanos SJ, Haynes JD, Narum DL.

Sci Rep. 2017 Dec 7;7(1):17146. doi: 10.1038/s41598-017-17505-9.

13.

Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission Intensities in Western Kenya.

Weber GE, White MT, Babakhanyan A, Sumba PO, Vulule J, Ely D, John C, Angov E, Lanar D, Dutta S, Narum DL, Horii T, Cowman A, Beeson J, Smith J, Kazura JW, Dent AE.

Sci Rep. 2017 Dec 4;7(1):16821. doi: 10.1038/s41598-017-17084-9.

14.

Protein-Specific Features Associated with Variability in Human Antibody Responses to Plasmodium falciparum Malaria Antigens.

Liu EW, Skinner J, Tran TM, Kumar K, Narum DL, Jain A, Ongoiba A, Traoré B, Felgner PL, Crompton PD.

Am J Trop Med Hyg. 2018 Jan;98(1):57-66. doi: 10.4269/ajtmh.17-0437. Erratum in: Am J Trop Med Hyg. 2018 Feb;98(2):636.

15.

A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection.

Srinivasan P, Baldeviano GC, Miura K, Diouf A, Ventocilla JA, Leiva KP, Lugo-Roman L, Lucas C, Orr-Gonzalez S, Zhu D, Villasante E, Soisson L, Narum DL, Pierce SK, Long CA, Diggs C, Duffy PE, Lescano AG, Miller LH.

NPJ Vaccines. 2017;2. pii: 14. doi: 10.1038/s41541-017-0015-7. Epub 2017 May 22.

16.

Effect of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali.

Mahamar A, Issiaka D, Barry A, Attaher O, Dembele AB, Traore T, Sissoko A, Keita S, Diarra BS, Narum DL, Duffy PE, Dicko A, Fried M.

Malar J. 2017 Jul 18;16(1):289. doi: 10.1186/s12936-017-1935-4.

17.

Decrease in Numbers of Naive and Resting B Cells in HIV-Infected Kenyan Adults Leads to a Proportional Increase in Total and Plasmodium falciparum-Specific Atypical Memory B Cells.

Frosch AE, Odumade OA, Taylor JJ, Ireland K, Ayodo G, Ondigo B, Narum DL, Vulule J, John CC.

J Immunol. 2017 Jun 15;198(12):4629-4638. doi: 10.4049/jimmunol.1600773. Epub 2017 May 19.

18.

Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.

Zhu D, Wu Y, McClellan H, Dai W, Rausch K, Jones D, Aebig J, Barnafo E, Butler B, Lambert L, Narum DL, Duffy PE.

Vaccine. 2017 May 31;35(24):3232-3238. doi: 10.1016/j.vaccine.2017.04.067. Epub 2017 May 4.

19.

Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance.

McCallum FJ, Persson KE, Fowkes FJ, Reiling L, Mugyenyi CK, Richards JS, Simpson JA, Williams TN, Gilson PR, Hodder AN, Sanders PR, Anders RF, Narum DL, Chitnis C, Crabb BS, Marsh K, Beeson JG.

J Leukoc Biol. 2017 Apr;101(4):913-925. doi: 10.1189/jlb.5MA0716-294R. Epub 2016 Nov 11.

20.

The Regulation of Inherently Autoreactive VH4-34-Expressing B Cells in Individuals Living in a Malaria-Endemic Area of West Africa.

Hart GT, Akkaya M, Chida AS, Wei C, Jenks SA, Tipton C, He C, Wendel BS, Skinner J, Arora G, Kayentao K, Ongoiba A, Doumbo O, Traore B, Narum DL, Jiang N, Crompton PD, Sanz I, Pierce SK.

J Immunol. 2016 Nov 15;197(10):3841-3849. Epub 2016 Oct 19.

21.

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.

Talaat KR, Ellis RD, Hurd J, Hentrich A, Gabriel E, Hynes NA, Rausch KM, Zhu D, Muratova O, Herrera R, Anderson C, Jones D, Aebig J, Brockley S, MacDonald NJ, Wang X, Fay MP, Healy SA, Durbin AP, Narum DL, Wu Y, Duffy PE.

PLoS One. 2016 Oct 17;11(10):e0163144. doi: 10.1371/journal.pone.0163144. eCollection 2016.

22.

Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.

MacDonald NJ, Nguyen V, Shimp R, Reiter K, Herrera R, Burkhardt M, Muratova O, Kumar K, Aebig J, Rausch K, Lambert L, Dawson N, Sattabongkot J, Ambroggio X, Duffy PE, Wu Y, Narum DL.

J Biol Chem. 2016 Sep 16;291(38):19913-22. doi: 10.1074/jbc.M116.732305. Epub 2016 Jul 18.

23.

VAR2CSA Domain-Specific Analysis of Naturally Acquired Functional Antibodies to Plasmodium falciparum Placental Malaria.

Doritchamou JY, Herrera R, Aebig JA, Morrison R, Nguyen V, Reiter K, Shimp RL, MacDonald NJ, Narum DL, Fried M, Duffy PE.

J Infect Dis. 2016 Aug 15;214(4):577-86. doi: 10.1093/infdis/jiw197. Epub 2016 May 18.

24.

A Method for Producing Protein Nanoparticles with Applications in Vaccines.

Jones DS, Rowe CG, Chen B, Reiter K, Rausch KM, Narum DL, Wu Y, Duffy PE.

PLoS One. 2016 Mar 7;11(3):e0138761. doi: 10.1371/journal.pone.0138761. eCollection 2016.

25.

Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting.

Charnaud SC, McGready R, Herten-Crabb A, Powell R, Guy A, Langer C, Richards JS, Gilson PR, Chotivanich K, Tsuboi T, Narum DL, Pimanpanarak M, Simpson JA, Beeson JG, Nosten F, Fowkes FJ.

Sci Rep. 2016 Feb 10;6:20859. doi: 10.1038/srep20859.

26.

Particle-based platforms for malaria vaccines.

Wu Y, Narum DL, Fleury S, Jennings G, Yadava A.

Vaccine. 2015 Dec 22;33(52):7518-24. doi: 10.1016/j.vaccine.2015.09.097. Epub 2015 Oct 11. Review.

27.

Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains.

Herrera R, Anderson C, Kumar K, Molina-Cruz A, Nguyen V, Burkhardt M, Reiter K, Shimp R Jr, Howard RF, Srinivasan P, Nold MJ, Ragheb D, Shi L, DeCotiis M, Aebig J, Lambert L, Rausch KM, Muratova O, Jin A, Reed SG, Sinnis P, Barillas-Mury C, Duffy PE, MacDonald NJ, Narum DL.

Infect Immun. 2015 Oct;83(10):3771-80. doi: 10.1128/IAI.02676-14. Epub 2015 Jul 13.

28.

Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display.

Crossey E, Frietze K, Narum DL, Peabody DS, Chackerian B.

PLoS One. 2015 Jul 6;10(7):e0132560. doi: 10.1371/journal.pone.0132560. eCollection 2015.

29.

Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria.

Srinivasan P, Ekanem E, Diouf A, Tonkin ML, Miura K, Boulanger MJ, Long CA, Narum DL, Miller LH.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10311-6. doi: 10.1073/pnas.1409928111. Epub 2014 Jun 23.

30.

Estimation of recent and long-term malaria transmission in a population by antibody testing to multiple Plasmodium falciparum antigens.

Ondigo BN, Hodges JS, Ireland KF, Magak NG, Lanar DE, Dutta S, Narum DL, Park GS, Ofulla AV, John CC.

J Infect Dis. 2014 Oct 1;210(7):1123-32. doi: 10.1093/infdis/jiu225. Epub 2014 Apr 15. Erratum in: J Infect Dis. 2015 Oct 1;212(7):1175.

31.

NOS2 variants reveal a dual genetic control of nitric oxide levels, susceptibility to Plasmodium infection, and cerebral malaria.

Trovoada Mde J, Martins M, Ben Mansour R, Sambo Mdo R, Fernandes AB, Antunes Gonçalves L, Borja A, Moya R, Almeida P, Costa J, Marques I, Macedo MP, Coutinho A, Narum DL, Penha-Gonçalves C.

Infect Immun. 2014 Mar;82(3):1287-95. doi: 10.1128/IAI.01070-13. Epub 2013 Dec 30.

32.

Disrupting malaria parasite AMA1-RON2 interaction with a small molecule prevents erythrocyte invasion.

Srinivasan P, Yasgar A, Luci DK, Beatty WL, Hu X, Andersen J, Narum DL, Moch JK, Sun H, Haynes JD, Maloney DJ, Jadhav A, Simeonov A, Miller LH.

Nat Commun. 2013;4:2261. doi: 10.1038/ncomms3261.

33.

Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development.

Richards JS, Arumugam TU, Reiling L, Healer J, Hodder AN, Fowkes FJ, Cross N, Langer C, Takeo S, Uboldi AD, Thompson JK, Gilson PR, Coppel RL, Siba PM, King CL, Torii M, Chitnis CE, Narum DL, Mueller I, Crabb BS, Cowman AF, Tsuboi T, Beeson JG.

J Immunol. 2013 Jul 15;191(2):795-809. doi: 10.4049/jimmunol.1300778. Epub 2013 Jun 17.

34.

Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.

Shimp RL Jr, Rowe C, Reiter K, Chen B, Nguyen V, Aebig J, Rausch KM, Kumar K, Wu Y, Jin AJ, Jones DS, Narum DL.

Vaccine. 2013 Jun 19;31(28):2954-62. doi: 10.1016/j.vaccine.2013.04.034. Epub 2013 Apr 24.

35.

The epitope of monoclonal antibodies blocking erythrocyte invasion by Plasmodium falciparum map to the dimerization and receptor glycan binding sites of EBA-175.

Ambroggio X, Jiang L, Aebig J, Obiakor H, Lukszo J, Narum DL.

PLoS One. 2013;8(2):e56326. doi: 10.1371/journal.pone.0056326. Epub 2013 Feb 15.

36.

Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.

Miura K, Herrera R, Diouf A, Zhou H, Mu J, Hu Z, MacDonald NJ, Reiter K, Nguyen V, Shimp RL Jr, Singh K, Narum DL, Long CA, Miller LH.

Infect Immun. 2013 May;81(5):1491-501. doi: 10.1128/IAI.01414-12. Epub 2013 Feb 19.

37.

Identification of VAR2CSA domain-specific inhibitory antibodies of the Plasmodium falciparum erythrocyte membrane protein 1 using a novel flow cytometry assay.

Obiakor H, Avril M, Macdonald NJ, Srinivasan P, Reiter K, Anderson C, Holmes KL, Fried M, Duffy PE, Smith JD, Narum DL, Miller LH.

Clin Vaccine Immunol. 2013 Mar;20(3):433-42. doi: 10.1128/CVI.00638-12. Epub 2013 Jan 23.

38.

Determination of protein concentration for protein-protein conjugates using ultraviolet absorption.

Zhu D, Qian F, Wu Y, Jones DS, Rowe C, Narum DL, Duffy P, Miller LH, Saul A.

J Immunol Methods. 2013 Jan 31;387(1-2):317-21. doi: 10.1016/j.jim.2012.10.011. Epub 2012 Oct 23.

39.

Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.

Ellis RD, Wu Y, Martin LB, Shaffer D, Miura K, Aebig J, Orcutt A, Rausch K, Zhu D, Mogensen A, Fay MP, Narum DL, Long C, Miller L, Durbin AP.

PLoS One. 2012;7(10):e46094. doi: 10.1371/journal.pone.0046094. Epub 2012 Oct 4.

40.

Binding of aldolase and glyceraldehyde-3-phosphate dehydrogenase to the cytoplasmic tails of Plasmodium falciparum merozoite duffy binding-like and reticulocyte homology ligands.

Pal-Bhowmick I, Andersen J, Srinivasan P, Narum DL, Bosch J, Miller LH.

MBio. 2012 Sep 18;3(5). pii: e00292-12. doi: 10.1128/mBio.00292-12. Print 2012.

41.

Broadly reactive antibodies specific for Plasmodium falciparum MSP-1(19) are associated with the protection of naturally exposed children against infection.

Dent AE, Moormann AM, Yohn CT, Kimmel RJ, Sumba PO, Vulule J, Long CA, Narum DL, Crabb BS, Kazura JW, Tisch DJ.

Malar J. 2012 Aug 21;11:287. doi: 10.1186/1475-2875-11-287.

42.

Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.

Wagner L, Verma A, Meade BD, Reiter K, Narum DL, Brady RA, Little SF, Burns DL.

Clin Vaccine Immunol. 2012 Sep;19(9):1465-73. doi: 10.1128/CVI.00174-12. Epub 2012 Jul 18.

43.

Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1.

Qian F, Reiter K, Zhang Y, Shimp RL Jr, Nguyen V, Aebig JA, Rausch KM, Zhu D, Lambert L, Mullen GE, Martin LB, Long CA, Miller LH, Narum DL.

PLoS One. 2012;7(6):e36996. doi: 10.1371/journal.pone.0036996. Epub 2012 Jun 4.

44.

Analysis of the conformation and function of the Plasmodium falciparum merozoite proteins MTRAP and PTRAMP.

Uchime O, Herrera R, Reiter K, Kotova S, Shimp RL Jr, Miura K, Jones D, Lebowitz J, Ambroggio X, Hurt DE, Jin AJ, Long C, Miller LH, Narum DL.

Eukaryot Cell. 2012 May;11(5):615-25. doi: 10.1128/EC.00039-12. Epub 2012 Mar 30.

45.

Plasmodium falciparum merozoite surface protein 1 blocks the proinflammatory protein S100P.

Waisberg M, Cerqueira GC, Yager SB, Francischetti IM, Lu J, Gera N, Srinivasan P, Miura K, Rada B, Lukszo J, Barbian KD, Leto TL, Porcella SF, Narum DL, El-Sayed N, Miller LH, Pierce SK.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5429-34. doi: 10.1073/pnas.1202689109. Epub 2012 Mar 19.

46.

Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.

McCarra MB, Ayodo G, Sumba PO, Kazura JW, Moormann AM, Narum DL, John CC.

Pediatr Infect Dis J. 2011 Dec;30(12):1037-42. doi: 10.1097/INF.0b013e31822d1451.

47.

Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion.

Srinivasan P, Beatty WL, Diouf A, Herrera R, Ambroggio X, Moch JK, Tyler JS, Narum DL, Pierce SK, Boothroyd JC, Haynes JD, Miller LH.

Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13275-80. doi: 10.1073/pnas.1110303108. Epub 2011 Jul 25.

48.

Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic.

Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, Lanar DE, Dutta S, Rosenthal PJ, Dorsey G, John CC.

J Infect Dis. 2011 Jul 1;204(1):19-26. doi: 10.1093/infdis/jir223.

49.

Delineation of stage specific expression of Plasmodium falciparum EBA-175 by biologically functional region II monoclonal antibodies.

Sim BK, Narum DL, Chattopadhyay R, Ahumada A, Haynes JD, Fuhrmann SR, Wingard JN, Liang H, Moch JK, Hoffman SL.

PLoS One. 2011 Apr 14;6(4):e18393. doi: 10.1371/journal.pone.0018393.

50.

Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques.

Hamid MM, Remarque EJ, El Hassan IM, Hussain AA, Narum DL, Thomas AW, Kocken CH, Weiss WR, Faber BW.

Malar J. 2011 Feb 8;10:29. doi: 10.1186/1475-2875-10-29.

Supplemental Content

Loading ...
Support Center